In phase II/III studies, NGR-TNF-α showed manageable toxicity and promising activity in primary central nervous system lymphoma [87], small cell lung cancer [88], and malignant pleural mesothelioma [89] (Table 1). This evidence concerns the gene TNF and small cell lung carcinoma.